Literatura académica sobre el tema "Ozanimod"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Ozanimod".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Ozanimod"
Daykin, Nicola. "Ozanimod for relapsing remitting multiple sclerosis and how Brexit changed the journey". Journal of Prescribing Practice 4, n.º 2 (2 de febrero de 2022): 64–71. http://dx.doi.org/10.12968/jprp.2022.4.2.64.
Texto completoHarris, Sarah, Jonathan Q. Tran, Harry Southworth, Collin M. Spencer, Bruce A. C. Cree y Scott S. Zamvil. "Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS". Neurology - Neuroimmunology Neuroinflammation 7, n.º 5 (31 de julio de 2020): e839. http://dx.doi.org/10.1212/nxi.0000000000000839.
Texto completoCohen, Jeffrey A., Giancarlo Comi, Douglas L. Arnold, Amit Bar-Or, Krzysztof W. Selmaj, Lawrence Steinman, Eva K. Havrdová et al. "Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study". Multiple Sclerosis Journal 25, n.º 9 (25 de julio de 2018): 1255–62. http://dx.doi.org/10.1177/1352458518789884.
Texto completoPanaccione, R., S. Danese, D. C. Wolf, J. B. Canavan, A. Jain, H. Wu, A. Petersen, A. Afzali y M. T. Abreu. "P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis". Journal of Crohn's and Colitis 17, Supplement_1 (30 de enero de 2023): i591—i593. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0594.
Texto completoSandborn, William, Brian Feagan, Douglas Wolf, Geert D’Haens, Séverine Vermeire, Stephen Hanauer, Subrata Ghosh, Harry Southworth y Sarah Harris. "EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS". Inflammatory Bowel Diseases 27, Supplement_1 (1 de enero de 2021): S6. http://dx.doi.org/10.1093/ibd/izaa347.014.
Texto completoArmuzzi, A., R. K. Cross, G. Lichtenstein, J. Calkwood, A. Pai, M. Pondel, H. A. Ahmad et al. "DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i094—i095. http://dx.doi.org/10.1093/ecco-jcc/jjab232.084.
Texto completoSiegmund, B., J. Axelrad, M. Pondel, M. T. Osterman, H. A. Ahmad, A. Memaj, M. Regueiro, A. Armuzzi y A. Afzali. "DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North". Journal of Crohn's and Colitis 16, Supplement_1 (1 de enero de 2022): i092—i093. http://dx.doi.org/10.1093/ecco-jcc/jjab232.082.
Texto completoDubinsky, M. C., U. Mahadevan, L. Charles, S. Afsari, A. Henry, G. Comi, K. Selmaj y C. J. van der Woude. "DOP53 Pregnancy outcomes in the ozanimod clinical development program in relapsing multiple sclerosis, Ulcerative Colitis, and Crohn’s Disease". Journal of Crohn's and Colitis 15, Supplement_1 (1 de mayo de 2021): S088—S089. http://dx.doi.org/10.1093/ecco-jcc/jjab073.092.
Texto completoShen, J., D. Tatosian, L. Sid-Otmane, N. Teuscher, L. Chen, P. Zhang, G. S. Tirucherai, D. Chitakara y C. Marta. "P332 Population pharmacokinetics of ozanimod and active metabolite CC112273 in patients with ulcerative colitis". Journal of Crohn's and Colitis 15, Supplement_1 (1 de mayo de 2021): S355—S357. http://dx.doi.org/10.1093/ecco-jcc/jjab076.456.
Texto completoShen, Jun, Daniel Tatosian, Lamia Sid-Otmane, Nathan Teuscher, Lu Chen, Peijin Zhang, Giridhar Tirucherai, Denesh Chitkara y Cecilia Marta. "POPULATION PHARMACOKINETICS OF OZANIMOD AND ACTIVE METABOLITE CC112273 IN PATIENTS WITH ULCERATIVE COLITIS". Inflammatory Bowel Diseases 28, Supplement_1 (22 de enero de 2022): S17—S18. http://dx.doi.org/10.1093/ibd/izac015.025.
Texto completoTesis sobre el tema "Ozanimod"
CIANFEROTTI, CLAUDIO. "Synthetic approaches to novel linkers for the bioconjugation of pharmaceutical active compounds". Doctoral thesis, Università di Siena, 2019. http://hdl.handle.net/11365/1071010.
Texto completoAntibody-Drug Conjugates (ADCs) are emerging as the next generation anticancer therapeutic agents. ADCs take advantage of the specificity of monoclonal antibody to target the delivery of drugs to the tumor site, with an expectation of improving the efficacy and safety of the cytotoxic payload. The linker plays a key role in the development of ADC derivatives and its blood stability as well as its possible degradation into the cell need to be carefully tuned. The synthesis of the linker offers many opportunities for organic chemistry. In this thesis we explored several different aspects of the ADC field. We developed the first ADC charged with a hydroxamic acid payload (the HDAC inhibitor vorinostat), connected through a metabolic sensitive linker. Moreover, the presence of a not highly cytotoxic drug leads to a lower systemic toxicity compared the one generally observed with traditional ADCs. With regard to self-immolative spacers, we designed a novel multifunctional branched linker that offers the opportunity of a modular synthesis of the various ADCs components. This linker is able to release a model of an amine payload from a disulfide trigger moiety. Furthermore, we present also studies towards a convergent approach to the synthesis of the linker. Besides the work on bioconjugates, we report the preparation of several synthetic impurities of the melatonin receptors agonist Tasimelteon and a new protecting group-free stereoselective synthesis of the sphingosine-1-phosphate receptor agonist Ozanimod.
Actas de conferencias sobre el tema "Ozanimod"
Venkatesan, Reshmii, Somaiah Chinnapaka, John Schappert y Gnanasekar Munirathinam. "Abstract 2974: Preclinical evaluation of Ozanimod for prostate cancer treatment". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2974.
Texto completoVenkatesan, Reshmii, Somaiah Chinnapaka, John Schappert y Gnanasekar Munirathinam. "Abstract 2974: Preclinical evaluation of Ozanimod for prostate cancer treatment". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2974.
Texto completoKammerer, Susanne. "Fast recapture of response with ozanimod after withdrawal in UC". En UEGW Week 2022, editado por Marjolijn Duijvestein. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/49a646b8.
Texto completoKammerer, Susanne. "Ozanimod treatment prompted substantial response after failure of response to induction". En UEGW Week 2022, editado por Marjolijn Duijvestein. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/83087d65.
Texto completoMarsolais, D., N. Châteauvert, P. Blais-Lecours, P. Rola, T. Nguyen y F. Lellouche. "A pilot trial for ozanimod therapy in hospitalized COVID-19 patients". En ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.520.
Texto completoTaylor, Carly, Timothy Waterhouse, Michael Heathman, D. Alex Oh, H. Kiyomi Komori y John S. Grundy. "P206 Model-predicted lymphocyte response and recovery profiles for the sphingosine 1-phosphate receptor modulators ozanimod and etrasimod". En Abstracts of the BSG Annual Meeting, 20–23 June 2022. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2022. http://dx.doi.org/10.1136/gutjnl-2022-bsg.260.
Texto completoHarris, Sarah, Giancarlo Comi, Bruce AC Cree, Lawrence Steinman, James K. Sheffield, Harry Southworth, Ludwig Kappos y Jeffrey A. Cohen. "067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials". En ANZAN Annual Scientific Meeting 2021 Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjno-2021-anzan.67.
Texto completoSiegmund, B., W. Sandborn, G. D’Haens, D. Wolf, S. Hanauer, I. Jovanovic, S. Ghosh et al. "Ozanimod for moderate-to-severe Ulcerative Colitis (UC): efficacy, safety, and histology results from the induction and maintenance periods of the Phase 3 TRUE NORTH Study". En Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1733513.
Texto completoSiegmund, B., W. Sandborn, G. D’Haens, D. Wolf, S. Hanauer, I. Jovanovic, S. Ghosh et al. "Ozanimod for moderate-to-severe Ulcerative Colitis (UC): efficacy, safety, and histology results from the induction and maintenance periods of the Phase 3 TRUE NORTH Study". En Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1733513.
Texto completo